Risk of tuberculosis after initiation of antiretroviral therapy among persons with HIV in Europe
Johansen, Isik Somuncu (University of Southern Denmark)
Roen, Ashley (University College London)
Kraef, Christian (University of Copenhagen)
Martín-Iguacel, Raquel (Odense University Hospital (Dinamarca))
Nemeth, Johannes (University of Zurich)
Fenner, Lukas (University of Bern)
Zangerle, Robert (Medizinische Universität Innsbruck)
Llibre, Josep M (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Miller, Robert (University College London)
Suarez, Isabelle (University of Cologne)
de Wit, Stephane (Centre de Recherche en Maladies Infectieuses a.s.b.l.)
Wit, Ferdinand WNM (HIV Monitoring Foundation)
Mussini, Christina (Università degli Studi di Modena)
Saracino, Annalisa (Italian Cohort Naive Antiretrovirals (ICONA))
Canetti, Diana (Università Vita-Salute San Raffaele)
Volny-Anne, Alain (European AIDS Treatment Group (EATG))
Jaschinski, Nadine (University of Copenhagen)
Neesgaard, Bastian (University of Copenhagen)
Ryom, Lene (University of Copenhagen)
Peters, Lars (University of Copenhagen)
Garges, Harmony (ViiV Healthcare)
Rooney, James F (Gilead Sciences)
Podlekareva, Daria (Copenhagen University Hospital)
Mocroft, Amanda (University College London)
Kirk, Ole (University of Copenhagen)

Data:	2024
Resum:	Objectives: Tuberculosis (TB) risk after initiation of antiretroviral treatment (ART) is not well described in a European setting, with an average TB incidence of 25/10 in the background population. Methods: We included all adult persons with HIV starting ART in the RESPOND cohort between 2012 and 2020. TB incidence rates (IR) were assessed for consecutive time intervals post-ART initiation. Risk factors for TB within 6 months from ART initiation were evaluated using Poisson regression models. Results: Among 8441 persons with HIV, who started ART, 66 developed TB during 34,239 person-years of follow-up (PYFU), corresponding to 1. 87/1000 PYFU (95% confidence interval [CI]: 1. 47-2. 37). TB IR was highest in the first 3 months after ART initiation (14. 41/1000 PY (95%CI 10. 08-20. 61]) and declined at 3-6, 6-12, and >12 months post-ART initiation (5. 89 [95%CI 3. 35-10. 37], 2. 54 [95%CI 1. 36-4. 73] and 0. 51 [95%CI 0. 30-0. 86]), respectively. Independent risk factors for TB within the first 6 months after ART initiation included follow-up in Northern or Eastern Europe region, African origin, baseline CD4 count <200 cells/mm, HIV RNA >100,000 copies/mL, injecting drug use and heterosexual transmission. Conclusions: TB IR was highest in the first 3 months post-ART initiation and was associated with baseline risk factors, highlighting the importance of thorough TB risk assessment at ART initiation.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	TB/HIV ; AIDS ; ART ; Incidence
Publicat a:	International journal of infectious diseases, Vol. 147 (October 2024) , ISSN 1878-3511

DOI: 10.1016/j.ijid.2024.107199

9 p, 1.0 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats